கிறிஸ்துவர் இடையூறு செய்பவர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host a series of virtual Research & Development events in 2021, with the first one scheduled for Monday, January 25, 2021, 11 a.m. to 1 p.m. ET.
The first event will focus on Passage Bio’s lead investigational therapy PBGM01 and its disease target, infantile GM1 gangliosidosis (GM1). Presenters for the event are:
Bruce Goldsmith, Ph.D., chief executive officer, who will present an overview of the Passage Bio pipeline and the GM1 disease and patient experience. ....

United States , University Of Pennsylvania , Gwen Fisher , Jamesm Wilson , Christian Hinderer , Bruce Goldsmith , Sarah Mccabe , Zofia Mita , Gary Romano , Stern Investor Relations Inc , University Of Pennsylvania Gene Therapy Program , European Commission , Passage Bio Inc , Research Development , Gene Therapy Program , Exchange Commission , University Of Pennsylvania Penn , Passage Bio , Orphan Drug Designations , Rare Pediatric Disease Designation , Private Securities Litigation Reform Act , Risk Factors , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா , க்வென் மீனவர் ,